A three-gene (CSAD, GOT2, and SOCS2) signature regulated by METTL14 is efficient for the prognostication of HCC (Li et al., 2020), which suggests that m6A regulators have a clinical prognostic impact in HCC. This evidence concerns the gene METTL14 and hepatocellular carcinoma.